Abstract:Brown seaweeds rich in flavonoids and bioactive polysaccharides have shown potential effects of suppressing fat accumulation, oxidative stress, and inflammation in the liver. Refined seaweed compounds such as low‐molecular‐weight fucoidan and high‐stability fucoxanthin, have not been well studied regarding their biological function. Nonalcoholic fatty liver disease (NAFLD) is one of the most common liver diseases and is characterized by parameters of liver function and metabolic profiles. Therefore, the aim of this study was to determine the combined effect of fucoidan and fucoxanthin on NAFLD with respect to the biochemical parameters. Seventy patients with NAFLD confirmed by abdominal echography and FibroScan were screened. Patients with seafood allergy and those taking vitamin E, pioglitazone, or liraglutide were excluded. Forty‐two patients were randomly divided into a group receiving either fucoidan‐fucoxanthin mixture or placebo. Both groups were subjected to 12‐week follow‐up. The degree of fatty liver and liver fibrosis was detected using transient elastography (TE) with a controlled attenuation parameter (CAP) (FibroScan). The biochemistry of creatine, aspartate aminotransferase, alanine aminotransferase (ALT), and fasting blood sugar (FBS) was monitored every 4 weeks during the follow‐up period. Moreover, the metabolic profile, including cholesterol, triglyceride, adiponectin, leptin, uric acid, and insulin, as well as complete blood count/differential count and C‐reactive protein were measured at baseline, 4th, and 12th week of follow‐up. There were no significant differences in the baseline of age, gender, BMI (body mass index), and severity of fibrosis in both groups, but more severe steatosis was observed in the treatment group. Combined supplementation of fucoidan and fucoxanthin led to a significant reduction of serum ALT compared to the control (P < 0.05). No prominent change was detected in the CAP and adiponectin, which may imply that this short intervention is not enough to improve NAFLD in patients receiving fucoidan‐fucoxanthin binary mixture. In this pilot study, the seaweed derivative mixture can significantly reduce ALT, indicating that the combination of fucoidan and fucoxanthin might be a novel hepatoprotective supplement for NAFLD patients.

Role of Fucus VesiculosusL. Alga in Promoting Thyroid Function in Experimental Rats

The Hypocholesterolemic Potential of the Edible Algae Fucus vesiculosus: Proteomic and Quantitative PCR Analysis

Protective effects of a mixed plant extracts derived from Astragalus membranaceus and Laminaria japonica on PTU-induced hypothyroidism and liver damages

Fucoidans from Pearsonothuria Graeffei Prevent Obesity by Regulating Intestinal Lipid Metabolism and Inflammation Related Signalling Pathways

Sulfated rhamnoglucan heteropolysaccharide of Spirulina platensis attenuates methimazole-induced hypothyroidism in rats

Seaweeds in the Oncology Arena: Anti-Cancer Potential of Fucoidan as a Drug—A Review

Thyroid Hormone Attenuate Nonalcoholic Fatty Liver Disease Via Inducing Autophagy In Rats

The Ameliorative Effects of Fucoidan in Thioacetaide-Induced Liver Injury in Mice

Hypolipidemic effect of brown seaweed (Sargassum crassifolium) extract in vivo (Study of histopathology, mRNA expression, and immunohistochemistry (IHC) with VCAM-1, ICAM-1, and MCP-1 parameters)

Elimination of Ethanol for the Production of Fucoidans from Brown Seaweeds: Characterization and Bioactivities

In vitro anticancer potential of laminarin and fucoidan from Brown seaweeds

Evaluation of the Effects of Fucoidans from Fucus Species and Laminaria hyperborea against Oxidative Stress and Iron-Dependent Cell Death

In Vitro Anti-Inflammatory Activities of Fucoidans from Five Species of Brown Seaweeds

A comparative study of the hypolipidemic effects and mechanisms of action of Laminaria japonica - and Ascophyllum nodosum -derived fucoidans in apolipoprotein E-deficient mice

Extraction, purification, structural characterization and anti-hyperlipidemia activity of fucoidan from Laminaria digitata

Dietary fucoidan extracted from macroalgae Saccharina japonica alleviate the hepatic lipid accumulation of black seabream (Acanthopagrus schlegelii)

Low‐molecular‐weight fucoidan and high‐stability fucoxanthin decrease serum alanine transaminase in patients with nonalcoholic fatty liver disease—A double‐blind, randomized controlled trial

Preclinical Evaluation of Safety of Fucoidan Extracts From Undaria pinnatifida and Fucus vesiculosus for Use in Cancer Treatment

A comprehensive review to assess the potential, health benefits and complications of fucoidan for developing as functional ingredient and nutraceutical

Exploring the Hypocholesterolemic Potential of a Fucus vesiculosus Extract: Omic Insights into Molecular Mechanisms at the Intestinal Level

Therapeutic Effects of Fucoidan: A Review on Recent Studies